Tianjin Chase Sun Pharmaceutical Co.,Ltd (SHE:300026)

Market Cap	9.22B -16.3%
Revenue (ttm)	4.68B -18.1%
Net Income	23.88M +0.9%
EPS	0.01 +14.4%
Shares Out	3.00B
PE Ratio	246.43
Forward PE	n/a
Dividend	0.01 (0.33%)
Ex-Dividend Date	Jun 24, 2025

Volume	28,635,849
Open	3.130
Previous Close	3.010
Day's Range	2.980 - 3.130
52-Week Range	2.990 - 4.490
Beta	0.04
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 28, 2026

About SHE:300026

Tianjin Chase Sun Pharmaceutical Co.,Ltd engages in the research and development, production, and sale of various pharmaceutical products in China and internationally. The company provides Chinese medicine formula granules, finished drugs, raw materials, medical devices and excipients, medical and health services, as well as smart supply chain for pharmaceuticals and medical devices. It serves the fields of immunity, cardiovascular and cerebrovascular diseases, respiratory system, and neurodegenerative diseases. The company was founded in 1996 ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1996
• Employees: 4,852
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 300026

Financial Performance

In 2025, SHE:300026's revenue was 4.94 billion, a decrease of -14.55% compared to the previous year's 5.78 billion. Earnings were 18.50 million, a decrease of -13.85%.